Gastropraxis Magdeburg
- Address
- lock Available on a paid plan
Digestive System Diseases
Research at Gastropraxis Magdeburg targets inflammatory bowel conditions, especially ulcerative colitis, aiming to improve remission rates and endoscopic healing.
- Oral controlled‑ileocolonic‑release nicotinamide therapy
- Top‑down biologic treatment with mirikizumab
- Assessment of disease activity through endoscopic and histologic endpoints
Gastropraxis Magdeburg is advancing therapeutic options for patients with mild to moderate disease, seeking faster symptom relief.
Immune System Diseases
The center investigates immune‑modulating strategies for Crohn’s disease and ulcerative colitis, reflecting the immune basis of these disorders.
- Comparative efficacy of mirikizumab versus azathioprine
- Long‑term remission and comprehensive disease control
- Pharmacokinetic study of mirikizumab in lactating individuals
Through these studies, Gastropraxis Magdeburg contributes to understanding how targeted biologics can reshape treatment paradigms for immune‑mediated gut diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gastropraxis Magdeburg
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Comparative Efficacy of Mirikizumab Versus Azathioprine and Glucocorticoids in Newly Diagnosed Moderate-to-Severe Ulcerative Colitis: A 52-Week Randomized Trial | Universitaetsklinikum Schleswig-Holstein AöR | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azathioprine | 2 | Unknown | 2025-12-05 | 2025-12-05 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.